Publication Information

{'id': 'https://openalex.org/W3031689938', 'doi': 'https://doi.org/10.3760/cma.j.issn.1673-4181.2019.01.016', 'title': 'Research progress in immunotherapy against PD-1/PD-L1 for advanced urothelial carcinoma', 'display_name': 'Research progress in immunotherapy against PD-1/PD-L1 for advanced urothelial carcinoma', 'publication_year': 2019, 'publication_date': '2019-02-28', 'ids': {'openalex': 'https://openalex.org/W3031689938', 'doi': 'https://doi.org/10.3760/cma.j.issn.1673-4181.2019.01.016', 'mag': '3031689938'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'http://rs.yiigle.com/CN121382201901/1125434.htm', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764547098', 'display_name': 'Guoji shengwu yixue gongcheng zazhi', 'issn_l': '1673-4181', 'issn': ['1673-4181'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4364118890', 'host_organization_name': 'Consortium eLearning Network Private Limited', 'host_organization_lineage': ['https://openalex.org/P4364118890'], 'host_organization_lineage_names': ['Consortium eLearning Network Private Limited'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': [], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5100769819', 'display_name': 'Dawei Tian', 'orcid': 'https://orcid.org/0000-0003-1428-4422'}, 'institutions': [{'id': 'https://openalex.org/I5740404', 'display_name': 'Tianjin Medical University', 'ror': 'https://ror.org/02mh8wx89', 'country_code': 'CN', 'type': 'education', 'lineage': ['https://openalex.org/I5740404']}, {'id': 'https://openalex.org/I4210133270', 'display_name': 'Second Hospital of Tianjin Medical University', 'ror': 'https://ror.org/03rc99w60', 'country_code': 'CN', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210133270']}], 'countries': ['CN'], 'is_corresponding': True, 'raw_author_name': 'Dawei Tian', 'raw_affiliation_strings': ['Department of Urology, the Secondary Hospital of Tianjin Medical University; Tianjin Institute of Urology, Tianjin 300211, China'], 'affiliations': [{'raw_affiliation_string': 'Department of Urology, the Secondary Hospital of Tianjin Medical University; Tianjin Institute of Urology, Tianjin 300211, China', 'institution_ids': ['https://openalex.org/I5740404', 'https://openalex.org/I4210133270']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 2, 'corresponding_author_ids': ['https://openalex.org/A5100769819'], 'corresponding_institution_ids': ['https://openalex.org/I5740404', 'https://openalex.org/I4210133270'], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 61}, 'biblio': {'volume': '42', 'issue': '1', 'first_page': '88', 'last_page': '93'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10458', 'display_name': 'Bladder and Urothelial Cancer Treatments', 'score': 0.9997, 'subfield': {'id': 'https://openalex.org/subfields/2746', 'display_name': 'Surgery'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10458', 'display_name': 'Bladder and Urothelial Cancer Treatments', 'score': 0.9997, 'subfield': {'id': 'https://openalex.org/subfields/2746', 'display_name': 'Surgery'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T12695', 'display_name': 'Urinary and Genital Oncology Studies', 'score': 0.9895, 'subfield': {'id': 'https://openalex.org/subfields/2746', 'display_name': 'Surgery'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10158', 'display_name': 'Cancer Immunotherapy and Biomarkers', 'score': 0.9877, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/atezolizumab', 'display_name': 'Atezolizumab', 'score': 0.9604676}, {'id': 'https://openalex.org/keywords/durvalumab', 'display_name': 'Durvalumab', 'score': 0.9014244}, {'id': 'https://openalex.org/keywords/avelumab', 'display_name': 'Avelumab', 'score': 0.8504571}, {'id': 'https://openalex.org/keywords/metastatic-urothelial-carcinoma', 'display_name': 'Metastatic Urothelial Carcinoma', 'score': 0.7184725}], 'concepts': [{'id': 'https://openalex.org/C2780057760', 'wikidata': 'https://www.wikidata.org/wiki/Q13896859', 'display_name': 'Pembrolizumab', 'level': 4, 'score': 0.96861696}, {'id': 'https://openalex.org/C2775949291', 'wikidata': 'https://www.wikidata.org/wiki/Q20707748', 'display_name': 'Atezolizumab', 'level': 5, 'score': 0.9604676}, {'id': 'https://openalex.org/C2777742743', 'wikidata': 'https://www.wikidata.org/wiki/Q19904005', 'display_name': 'Durvalumab', 'level': 5, 'score': 0.9014244}, {'id': 'https://openalex.org/C2777381376', 'wikidata': 'https://www.wikidata.org/wiki/Q21083261', 'display_name': 'Avelumab', 'level': 5, 'score': 0.8504571}, {'id': 'https://openalex.org/C2780030458', 'wikidata': 'https://www.wikidata.org/wiki/Q7041828', 'display_name': 'Nivolumab', 'level': 4, 'score': 0.80419004}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.7928058}, {'id': 'https://openalex.org/C2911057145', 'wikidata': 'https://www.wikidata.org/wiki/Q2501186', 'display_name': 'Metastatic Urothelial Carcinoma', 'level': 5, 'score': 0.7184725}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.6238176}, {'id': 'https://openalex.org/C2778239845', 'wikidata': 'https://www.wikidata.org/wiki/Q412415', 'display_name': 'Cisplatin', 'level': 3, 'score': 0.57479453}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.5388536}, {'id': 'https://openalex.org/C535046627', 'wikidata': 'https://www.wikidata.org/wiki/Q30612', 'display_name': 'Clinical trial', 'level': 2, 'score': 0.5175978}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.49049634}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.43478844}, {'id': 'https://openalex.org/C3019882237', 'wikidata': 'https://www.wikidata.org/wiki/Q2501186', 'display_name': 'Urothelial carcinoma', 'level': 4, 'score': 0.2750392}, {'id': 'https://openalex.org/C2780352672', 'wikidata': 'https://www.wikidata.org/wiki/Q504775', 'display_name': 'Bladder cancer', 'level': 3, 'score': 0.25573176}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.19588566}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'http://rs.yiigle.com/CN121382201901/1125434.htm', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S2764547098', 'display_name': 'Guoji shengwu yixue gongcheng zazhi', 'issn_l': '1673-4181', 'issn': ['1673-4181'], 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/P4364118890', 'host_organization_name': 'Consortium eLearning Network Private Limited', 'host_organization_lineage': ['https://openalex.org/P4364118890'], 'host_organization_lineage_names': ['Consortium eLearning Network Private Limited'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'display_name': 'Good health and well-being', 'score': 0.77, 'id': 'https://metadata.un.org/sdg/3'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': [], 'abstract_inverted_index': {'Cisplatin-based': [0], 'chemotherapy': [1, 120], 'is': [2, 87, 113, 126], 'not': [3], 'effective': [4, 115, 128], 'in': [5, 67, 81, 106, 121, 129, 146], 'patients': [6, 53, 134, 150], 'with': [7, 54, 135, 151], 'advanced': [8, 55, 136], 'urothelial': [9, 56, 137, 156], 'carcinoma.': [10], 'Recently,': [11], 'the': [12, 39, 46, 49, 64, 68, 107, 117, 130], 'application': [13], 'of': [14, 51, 58, 76, 109, 132, 149], 'immunological': [15], 'checkpoint': [16, 158], 'inhibitors': [17], 'has': [18], 'brought': [19], 'new': [20], 'insight': [21], 'to': [22], 'resolve': [23], 'this': [24], 'problem.': [25], 'Since': [26], 'May': [27], '2016,': [28], 'five': [29], 'drugs,': [30], 'including': [31], 'Atezolizumab,': [32], 'Pembrolizumab,': [33], 'Nivolumab,': [34], 'Avelumab,': [35], 'and': [36, 61, 74, 141], 'Durvalumab,': [37], 'targeting': [38], 'PD-1/PD-L1': [40], 'pathway': [41], 'have': [42, 143], 'been': [43], 'approved': [44], 'by': [45, 89], 'FDA': [47], 'for': [48], 'treatment': [50, 131], 'cisplatin-ineligible': [52, 133], 'carcinoma,': [57, 138], 'which': [59], 'Pembrolizumab': [60, 86, 112, 140], 'Atezolizumab': [62, 142], 'are': [63, 79], 'first-line': [65], 'drugs': [66, 78], 'above': [69], 'treatments.': [70], 'The': [71, 102], 'clinical': [72, 100, 147], 'efficacy': [73, 145], 'safety': [75], 'these': [77], 'similar': [80, 144], 'different': [82], 'trials,': [83], 'but': [84], 'only': [85], 'supported': [88], 'a': [90, 96], 'current': [91], 'level': [92], 'I': [93], 'evidence': [94], 'from': [95], 'large': [97], 'randomized': [98], 'phase': [99], 'trials.': [101], 'results': [103], 'show': [104], 'that': [105], 'case': [108], 'cisplatin': [110, 152], 'ineligibility,': [111], 'more': [114], 'than': [116], 'traditional': [118], 'salvage': [119], 'overall': [122], 'survival': [123], 'rate.': [124], 'Pembrolizuma': [125], 'most': [127], 'while': [139], 'applications': [148], 'ineffective.\r\n\r\n\r\nKey': [153], 'words:': [154], '\r\nAdvanced': [155], 'carcinoma;\xa0Immune': [157], 'inhibitors;\xa0PD-1/PD-L1;\xa0Clinical': [159], 'trials': [160]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3031689938', 'counts_by_year': [], 'updated_date': '2024-12-15T21:08:35.618091', 'created_date': '2020-06-05'}